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ABSTRACT
Background
Pneumonia remains the leading cause of death in young children. The poor specificity of
chest radiographs (CXRs) to diagnose pneumococcal pneumonia may underestimate the
efficacy of pneumococcal conjugate vaccine in preventing pneumococcal pneumonia.
Methods and Findings
The efficacy of nine-valent pneumococcal conjugate vaccine among children not infected
with HIV (21%; 95% confidence interval, 1%–37%) increased when CXR-confirmed pneumonia
was associated with serum C-reactive protein of 120 mg/l (12mg/dl) or more and procalcitonin
of 5.0 ng/ml or more (64%; 95% confidence interval, 23%–83%). Similar results were observed
in children infected with HIV.
Conclusion
C-reactive protein and procalcitonin improve the specificity of CXR to diagnose pneumo-
coccal pneumonia and may be useful for the future evaluation of the effectiveness of
pneumococcal conjugate vaccine in preventing pneumococcal pneumonia.
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While pneumonia remains the leading cause of death in
children, the absence of sensitive and speciﬁc tools to make an
etiologicaldiagnosisisamajorlimitationtoourunderstanding
of the efﬁcacy of vaccines against pneumonia. Blood cultures
lack sensitivity, and cultures from lung aspirates may be inﬂu-
enced by delayed presentation, antecedent antibiotic therapy,
difﬁculties ﬁnding an accessible siteto aspirate, lack of skillsin
performingtheprocedure,andtheperceptionofbothparents
and clinicians that the procedure is too invasive [1,2].
Procalcitonin, at a low threshold ( 0.25 ng/ml), has been
shown to be useful in directing the use of antibiotics in adults
with pneumonia [3], and a recent meta-analysis concludes
that procalcitonin may offer some advantages over C-reactive
protein (CRP) for discriminating bacterial from nonbacterial
infections [4]. Most studies support the observation that
children with bacterial infections have higher levels of CRP
and procalcitonin than those with viral infections [4,5,6]. Our
recent observation that many children with viral-associated
pneumonia have a bacterial super-infection [7], however,
suggests that a high level of CRP and procalcitonin may be
associated with unrecognised bacterial co-infection in a child
with an established viral aetiology for pneumonia. This may
also explain why some studies have found procalcitonin and
CRP not to be useful in distinguishing between bacterial and
‘‘viral’’ pneumonia [4,8].
Based on the postulate that the most likely chest radiograph
(CXR) manifestation of pneumococcal pneumonia is alveolar
consolidation, we reported the efﬁcacy of a nine-valent
pneumococcal conjugate vaccine (PnCV) in reducing CXR-
conﬁrmed pneumonia based on deﬁnitions recommended by
a World Health Organization working group [9]. The observed
reduction in the incidence of CXR-conﬁrmed pneumonia in
the intent-to-treat analyses in PnCV recipients not infected
with HIV (20%; 95% conﬁdence interval [CI], 2% to 35%) and
infected with HIV (13%; 95% CI,  7% to 29%) likely
underestimated the reduction in the incidence of pneumo-
coccal pneumonia [10]. The reason for this is that the outcome
measure (i.e., CXR-conﬁrmed pneumonia) is not highly
speciﬁc for pneumococcal pneumonia. Consequently, it is
likely that many of the CXR-conﬁrmed pneumonia episodes
were not pneumococcal in origin and therefore could not
have been prevented by the vaccine under evaluation.
We thus evaluated the usefulness of procalcitonin and CRP
to improve the speciﬁcity of CXR-conﬁrmed pneumonia as
an endpoint in vaccine efﬁcacy trials. This analysis was not a
primary objective of the study, and is therefore an hypoth-
esis-generating analysis, which should be tested as an a priori
hypothesis in other study settings.
Methods
The methods of the randomised, double-blind, placebo-
controlled trial, the objectives of which were to measure
PnCV efﬁcacy against invasive pneumococcal disease and
CXR-conﬁrmed pneumonia, have been published [10] (Pro-
tocol S1). Brieﬂy stated, the study included 39,836 children,
including an estimated 6.47% infected with HIV [7], and was
performed in Soweto, South Africa. Children were rando-
mised to receive either a nine-valent PnCV conjugated to
CRM197 (Wyeth-Lederle Vaccines and Pediatrics, Pearl River,
New York, United States) or a placebo at 6, 10, and 14 wk of
age. The nine-valent PnCV included serotypes 1, 4, 5, 6B, 9V,
14, 18C, 19F, and 23F (i.e., vaccine serotypes) [10]. We now
further measured procalcitonin and CRP levels in serum
obtained within 12 h of hospitalisation among children with
CXR-conﬁrmed alveolar consolidation in the intent-to-treat
analysis. CXRs were requested for any child hospitalised with
a clinical diagnosis of lower respiratory tract infection
according to the diagnosis of the attending study-physician.
CRP values were determined at the time of admission by
immunoturbidometry (717 Automated Analyzer, Boehringer
Mannheim/Hitachi, Mannheim, Germany) and were reported
in milligrams per liter with a lower threshold set at 3 mg/l or
lower. In those children in whom CRP was not measured on
admission to hospital, archived serum obtained within 12 h of
admission and stored at  70 8C was used for analysis. The
archived serum samples were also used for measuring
quantitative procalcitonin levels using the LUMItest PCT
assay (BRAHMS Diagnostica, Berlin, Germany). The CRP and
procalcitonin tests were performed using commercially
available assays according to the manufacturers’ recommen-
dations at the National Health and Laboratory Services,
Johannesburg, South Africa.
Bacterial Cultures
Blood was cultured for bacterial growth on admission and
processed using the BacT/Alert microbial detection system
(Organon Teknika, Durham, North Carolina, United States).
Isolates of Streptococcus pneumoniae were serotyped using the
quellung method at the Respiratory and Meningeal Pathogens
Research Unit and the results validated at the Statens Serum
Institute in Copenhagen, Denmark [10].
Statistics
Data were analysed using STATA version 8.0 (StataCorp,
College Station, Texas, United States) and Epi Info version
6.04d (Centers for Disease Control and Prevention, Atlanta,
Georgia, United States). Vaccine efﬁcacy was calculated using
Epi Info based on the formula: vaccine efﬁcacy (percent) =
[(ARU   ARV)/ARU] 3 100, where ARU is attack rate in
unvaccinated individuals and ARV is attack rate in vaccinated
indivduals. The vaccine-attributable reduction in disease
(VAR) was estimated by measuring the difference in
incidence rate between vaccine and placebo recipients and
expressed per 100,000 child years of observation. A p-value of
0.05 or lower was considered signiﬁcant.
All analyses were performed on an intent-to-treat basis,
which included the ﬁrst event of CXR-conﬁrmed pneumonia
in any child who had received at least a single dose of study
vaccine. Vaccine efﬁcacy calculations were also performed
for bacteremic pneumococcal pneumonia that included all
ﬁrst episodes of pneumonia associated with growth of S.
pneumoniae of any serotype from blood.
Ethical Considerations
The efﬁcacy study and subsequent study evaluating the role
of procalcitonin and CRP in children with CXR-conﬁrmed
pneumonia were approved by the Ethics Committee for
Research on Human Subjects, University of the Witwaters-
rand, South Africa (Protocol S2). Guardians gave informed
consent for the collection of serum and its use for diagnostic
assays that may improve the diagnosis of pneumonia
(Protocol S3).
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In children not infected with HIV with CXR-conﬁrmed
pneumonia, procalcitonin and CRP values were available for
132 (78.1%) of 169 vaccine recipients and 167 (78.8%) of 212
placebo recipients (p=0.88). The point estimate of vaccine
efﬁcacy in this cohort of children for whom serum was
available was 21% (p=0.04; 95% CI 1%–37%), not
signiﬁcantly different from that determined in the original
study (20%, p=0.03; 95% CI 3%–35%). At CRP levels of 120
mg/l or more in conjunction with the primary CXR-
conﬁrmed outcome measure, the estimate of vaccine efﬁcacy
increased to 38% (p=0.05); at procalcitonin levels of 5 ng/ml
or more, the estimated efﬁcacy increased to 46% (p=0.04);
and if both conditions were met, the estimated efﬁcacy
increased to 64% (p = 0.006) (Table 1).
Among children infected with HIV with CXR-conﬁrmed
pneumonia, procalcitonin and CRP values were available for
139 (76.4%) of 182 vaccine recipients and 153 (73.2%) of 209
placebo recipients (p=0.47). Whereas vaccine efﬁcacy was
not signiﬁcant for CXR-conﬁrmed pneumonia (9%; p=0.38),
vaccine efﬁcacy was signiﬁcant when measured against CXR-
conﬁrmed pneumonia in conjunction with a CRP level of 120
mg/l or more (35%; p=0.03) or a procalcitonin level of 5 ng/
ml or more (33%; p=0.04). As observed in children not
infected with HIV, the point efﬁcacy estimate in children
infected with HIV with CXR-conﬁrmed pneumonia was
greatest if both CRP and procalcitonin were at or above
120 mg/l and 5 ng/ml, respectively (52%; p=0.004; Table 1).
The sensitivity of CXR-conﬁrmed pneumonia plus CRP
 120 mg/l plus procalcitonin  5 ng/ml in detecting vaccine
efﬁcacy against pneumococcal pneumonia was analysed by
comparing the VAR per 100,000 child years to that observed
using an outcome of bacteremic pneumococcal pneumonia.
In children not infected with HIV, the combined outcome of
CXR-conﬁrmed pneumonia plus CRP  120 mg/l plus
procalcitonin  5 ng/ml (VAR = 37) identiﬁed 5.3-fold more
cases of pneumonia that were prevented by vaccination than
was identiﬁed by bacteremic pneumococcal pneumonia (VAR
= 7) and 4.1-fold more cases than was identiﬁed by vaccine-
serotype-speciﬁc bacteremic pneumococcal pneumonia (VAR
= 9). Similarly, CXR-conﬁrmed pneumonia plus CRP  120
mg/l plus procalcitonin  5 ng/ml in children infected with
HIV (VAR = 772) identiﬁed 1.6-fold more cases of pneumo-
nia that were prevented by vaccination than was identiﬁed by
pneumococcal bacteremic pneumonia (VAR = 483) and 2.2-
fold more cases than was identiﬁed by vaccine-serotype-
speciﬁc bacteremic pneumococcal pneumonia (VAR = 344).
Among the children not infected with HIV with CXR-
conﬁrmed pneumonia, the likelihood of a difference between
placebo and vaccine recipients was signiﬁcantly increased by
the presence of a CRP level of 120 mg/l or more and a
procalcitonin level of 5 ng/ml or more (odds ratio = 1.37;
95% CI, 1.09–1.73; p=0.027). This was true also among
children infected with HIV (odds ratio = 1.41; 95% CI, 1.14–
1.75; p=0.005).
Discussion
Our results show that the true efﬁcacy of the PnCV against
pneumococcal pneumonia may be underestimated if one
relies solely on a radiological diagnosis of pneumococcal
pneumonia. The lack of speciﬁcity of CXRs for inferring
bacterial versus non-bacterial etiology of pneumonia has
been previously described [11,12]. The speciﬁcity of CXR-
conﬁrmed pneumonia as an outcome measure of efﬁcacy of
PnCV to prevent pneumococcal pneumonia was improved
when it was analysed together with indirect evidence
suggestive of bacterial infection, namely, elevated CRP and
procalcitonin levels. This outcome measure of CXR-con-
ﬁrmed pneumonia plus CRP  120 mg/l plus procalcitonin  5
ng/ml, while more speciﬁc than CXR-conﬁrmed pneumonia
alone, will not be 100% accurate because pneumonia
associated with other bacteria, including that due to pneumo-
coccal serotypes against which the PnCV has no effect, may
well present in a similar manner.
Table 1. CRPand Procalcitonin Improve the Specificity of CXR to Measure the Efficacy of PnCV in the Prevention of Pneumococcal
Pneumonia
Outcome Measure Children Not Infected with HIV Children Infected with HIV
PnCV
(n = 18,633)
Placebo
(n = 18,626)
Vaccine
Efficacy
95% CI p-Value PnCV
(n = 1,289)
Placebo
(n = 1,288)
Vaccine
Efficacy
95% CI p-Value
CXR-AC
a 132 167 21 1, 37 0.04 139 153 9  13, 27 0.38
CXR-AC þ PCT   2 ng/ml 40 52 23  16, 49 0.21 61 83 27  1, 47 0.06
CXR-AC þ PCT   4 ng/ml 23 37 38  5, 63 0.07 43 65 34 3, 55 0.03
CXR-AC þ PCT   5 ng/ml 19 35 46 5, 69 0.03 41 61 33 1, 54 0.04
CXR-AC þ CRP , 40 mg/l 68 82 17  14, 40 0.25 74 69  7  32, 28 0.67
CXR-AC þ CRP   40 mg/l 64 85 25  4, 46 0.08 65 84 23  6, 44 0.10
CXR-AC þ CRP   80 mg/l 42 61 31  2, 54 0.06 51 71 12  2, 50 0.06
CXR-AC þ CRP   120 mg/l 28 45 38 0, 61 0.05 40 61 35 3, 56 0.03
CXR-AC þ CRP   120 mg/l þ PCT   5 ng/ml 9 25 64 23, 83 0.006 21 44 52 20, 71 0.004
Bacteremic pneumococcal pneumonia
b 58 3 8  91, 80 0.42 17 31 45 1, 70 0.04
Vaccine serotype pneumococcal pneumonia
c 26 6 7  65, 93 0.18 7 17 59 1, 83 0.04
CXR-confirmed alveolar consolidation based on World Health Organization guidelines for interpretation. Point estimates differ from those previously published because only children with CXR-confirmed pneumonia for whom serum for CRP
and procalcitonin measurements were available are included.
a CXR-AC, CXR-confirmed alveolar consolidation; PCT, procalcitonin.
b Pneumonia associated with growth from blood of S. pneumoniae, of any serotype.
c Pneumonia associated with growth from blood of S. pneumoniae of vaccine-serotype-specific bacteremic pneumonia.
DOI: 10.1371/journal.pmed.0020038.t001
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improved speciﬁcity in diagnosing pneumococcal pneumo-
nia, may be that the criteria of CXR-conﬁrmed pneumonia
coupled with a CRP level of 120 mg/l or more and a
procalcitonin level of 5 ng/ml or more detected more severe
disease against which the vaccine may have been more
efﬁcacious. Although we are unaware of data to support that
CRP and procalcitonin are elevated in those with severe
pneumonia, the absence of such data supporting this
interpretation does not rule out this possibility.
Importantly, the levels of CRP and procalcitonin used in
this report are designed for speciﬁcity rather than sensitivity;
it would be inappropriate to use the same threshold values of
CRP or procalcitonin during the course of routine clinical
practice when managing individuals suspected of having
bacterial pneumonia. In that instance, it would be more
appropriate to use thresholds that have a high sensitivity, to
ensure that all children with possible bacterial infection are
adequately treated [3,4,8].
Procalcitonin and CRP were equally useful in children
infected and not infected with HIV to improve the speciﬁcity
of the pneumococcal pneumonia efﬁcacy endpoint in the
vaccine trial among children with CXR-conﬁrmed pneumo-
nia. This is particularly important, as our initial observation
of a non-signiﬁcant reduction in CXR-conﬁrmed pneumonia
was attributed to the complexity of etiology of pneumonia,
and thus the even poorer speciﬁcity of CXRs for identifying
pneumococcal pneumonia in children infected with HIV
compared to children not infected with HIV [13,14]. The
current study thus indicates that the speciﬁcity of CXR-
conﬁrmed pneumonia for diagnosing pneumococcal pneu-
monia may also be improved in children with HIV through
the concurrent use of procalcitonin and CRP.
A distinction must be made between measures of vaccine
efﬁcacy for which the increased speciﬁcity of CXR-conﬁrmed
pneumonia plus CRP  120 mg/l plus procalcitonin  5 ng/ml
over CXR-conﬁrmed pneumonia alone is apparent, and
studies of the burden of disease prevented (VAR), which are
optimised when vaccine sensitivity is maximised. Our data
show that the VAR is greater for CXR-conﬁrmed pneumonia
plus CRP  120 mg/l plus procalcitonin  5 ng/ml than that
calculated usingthevery highly speciﬁcendpoints of serotype-
speciﬁc or all-serotype pneumococcal bacteremic pneumonia.
The best estimates of VAR will, however, be provided by
endpoints that sacriﬁce some speciﬁcity for maximal sensi-
tivity. Such studies include less speciﬁc clinical endpoints and
are outside of the scope of the current analysis [7].
Our ﬁndings have implications for the planning of future
studies aimed at evaluating the effectiveness of pneumococcal
vaccines against bacterial pneumonia. Our data suggest that
the outcome measure of CXR-conﬁrmed pneumonia together
with elevated CRP and procalcitonin levels may be more
accurate as a surrogate of pneumococcal pneumonia than
CXRs on their own. The increased speciﬁcity of this endpoint
may allow smaller sample sizes for future vaccine efﬁcacy/
effectiveness studies. Based on the incidence of CXR-
conﬁrmed pneumonia in this report (167 [0.9%] of 18,626),
a sample size of 80,058 children were required to detect the
20% reduction in CXR-conﬁrmed pneumonia with 80%
power and an alpha of 0.05. The actual power for this out-
come in this study was thus only 46.8%. Using the more spe-
ciﬁc outcome measure of CXR-conﬁrmed pneumonia with a
CRP level of 120 mg/l or more and a procalcitonin level of 5
ng/ml or more, the sample size required to detect the obser-
ved 64% reduction in outcome was 44,734, i.e., 56% of the
sample size required when measuring vaccine efﬁcacy against
CXR-conﬁrmed pneumonia alone, and the power of the cur-
rent study would have been increased from 46.8% to 71.5%.
Our ﬁndings therefore suggest that CXR-conﬁrmed pneu-
monia coupled with serological markers of CRP and
procalcitonin is a more speciﬁc marker of pneumococcal
pneumonia and may therefore provide a closer estimate of
the efﬁcacy of the PnCV against pneumococcal pneumonia.
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Background Pneumonia is the leading cause of death in children
worldwide. Pneumonia can be caused by different bacteria and viruses,
and there are no easy diagnostic tests to find out which bacterium or
virus has caused the disease in a particular patient. This not only causes
problems with prescribing the best treatment, but also makes it hard to
evaluate vaccines that might protect against some causes of the disease
but not others.
Why Was This Study Done? The researchers involved in this study have
evaluated vaccines against a particular bacterium (called Pneumococcus)
that is the leading cause of pneumonia in children. They have begun to
test these vaccines in children, but were looking for more specific ways
to distinguish cases of pneumonia caused by this particular bacterium
from those caused by other bacteria or viruses.
What Did the Researchers Do? They had previously done a trial for a
vaccine that relied on chest X-rays to diagnose pneumonia. They had
also collected blood from children who had participated in the trial and
had become sick with pneumonia. They now checked those blood
samples for two markers that indicate a bacterial infection and re-
analyzed the study.
What Did They Find? The vaccine was able to protect children—to
some extent—against pneumonia. The vaccine appeared to offer greater
protection against pneumonia when the pneumonia was diagnosed by a
combination of X-rays and high levels of the two blood markers than
when the illness was diagnosed just with a chest X-ray.
What Does This Mean? These results raise the possibility that a
combined test (chest X-ray plus two blood markers) is better at assessing
whether the pneumonia vaccine works than just a chest X-ray alone.
What Next? Because of the way this study was done—adding a specific
analysis to a clinical trial after it was completed, rather than planning to
test a hypothesis from the outset—it cannot be considered as proof of
the idea tested. The results suggest that it is worth testing whether the
combined diagnosis is more specific for pneumococcal pneumonia than
chest X-rays alone, but new studies are needed to resolve the issue.
More Information Online The Global Alliance for Vaccines and
Immunization (GAVI): http://www.vaccinealliance.org/
GAVI Web page ‘‘Call for Intensified Research after Pneumococcus Trial
Surprises’’: http://www.vaccinealliance.org/Resources_Documents/
Immunization_Focus/Download/update.php
World Health Organization (WHO) Web site on vaccines: http://www.
who.int/vaccines/
WHO Web page ‘‘Pneumococcal Vaccines’’: http://www.who.int/
vaccines/en/olddocs/pneumococcus.shtml)
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